Compounded GLP-1: What You Need to Know About Safety, Cost, and FDA Guidance

Quick Answer

Compounded GLP-1 medications are cheaper alternatives to brand-name versions but carry significant risks — and the legal landscape just shifted. As of May 2026, semaglutide injection is no longer on the FDA Drug Shortage Database, meaning compounding pharmacies are supposed to stop making compounded semaglutide. The FDA has continued issuing warning letters about quality, purity, and effectiveness concerns. Hims stopped selling its compounded GLP-1 pill after legal pressure. And a new FDA-approved oral option (Foundayo) may reduce the need for compounding entirely.

For a deep dive on what specifically changed with compounded semaglutide in 2026, see our Compounded Semaglutide: What Changed, What's Legal, What to Verify page.

Key Points

• Semaglutide is off the shortage list — As of May 2026, semaglutide injection is no longer listed on the FDA Drug Shortage Database, making compounding legally riskier
• Compounded GLP-1s are not FDA-approved — They skip the rigorous safety and efficacy review that brand-name medications undergo
• Salt form risk — Some compounded products use semaglutide sodium/acetate salt, which the FDA says is a different active ingredient
• Quality varies widely — FDA inspectors found carpeted cleanrooms, 40% dosing errors, and microbial contamination at compounding facilities
• Hims exited the market — Stopped selling compounded GLP-1 pills in May 2026 after legal pressure
• New FDA-approved pill option — Foundayo (orforglipron) gives patients an oral alternative with expanding insurance coverage
• Manufacturer savings available — Novo Nordisk and Eli Lilly offer programs reducing costs to $99-$500/month for eligible patients

Statistics

• $200-500/month typical cost for compounded semaglutide vs. $900-$1,400/month for brand-name (GoodRx, 2026)
• Semaglutide removed from FDA shortage list in May 2026 — compounding now legally riskier (FDA Drug Shortage Database)
• Multiple FDA warning letters issued in 2026 documenting insanitary conditions, dosing errors, and contamination (FDA Safety Communications, 2023-2026)
• Salt forms are different molecules from FDA-approved semaglutide base (FDA Drug Shortage Task Force, 2024)
• Adverse events reported including hospitalizations, severe nausea, and ineffective treatment (FDA adverse event database, 2024)

Compounded semaglutide and tirzepatide are cheaper than brand-name versions—sometimes dramatically so. But they come with real risks that every GLP-1 user should understand before making a decision.

What Is Compounding?

Compounding is the practice of a pharmacy creating a customized version of a medication for an individual patient. It's a legitimate and important part of healthcare when:

• A patient is allergic to an ingredient in the commercially available product
• The needed dosage or form isn't commercially available
• A medication is on the FDA's drug shortage list

Compounded medications are prepared by licensed pharmacists in state-registered or FDA-registered compounding facilities. They are not the same as FDA-approved, mass-manufactured drugs.

Why Compounded GLP-1s Exist — And Why That's Changing

The FDA maintains a drug shortage list. When a commercially available drug is listed as being in shortage, compounders are legally permitted to create copies of that drug. But the shortage status has shifted significantly.

Current shortage status (as of June 2026):

• Semaglutide injection — Removed from the FDA Drug Shortage Database as of May 2026. This means compounding pharmacies are supposed to stop making compounded semaglutide. Some still operate, but the legal risk is now higher.
• Liraglutide — Remains on the FDA shortage list. Compounding liraglutide is still permitted under the shortage exemption.
• Tirzepatide — Has experienced periodic shortages. The FDA has also cited pharmacies for improper tirzepatide compounding.

Check the current status: Visit FDA.gov Drug Shortages for the most up-to-date shortage list.

When a drug is on the shortage list, compounding pharmacies can legally produce versions of it. When the shortage is resolved, they're supposed to stop. With semaglutide now off the list, the legal footing for compounding it has shifted — and the FDA has been increasing enforcement.

For the full breakdown of what changed, see Compounded Semaglutide in 2026: What Changed, What's Legal, What to Verify.

What Changed in 2026

The compounded GLP-1 landscape shifted significantly in 2026. Here are the key developments:

Semaglutide Removed from Shortage List

The biggest change: as of May 2026, semaglutide injection is no longer on the FDA Drug Shortage Database. This means compounding pharmacies are supposed to stop making compounded semaglutide. Some will comply; some may not. The FDA's enforcement track record suggests they will go after the worst offenders, but not every pharmacy will get inspected immediately.

FDA Warning Letters: Continued Enforcement

The FDA has continued issuing warning letters to compounding pharmacies in 2026. These are not abstract risks — they are real facilities where real patients received medications. Inspectors found:

• Sterile injections being filled on a benchtop table in a room with carpeted floors
• A blood sample centrifuge running in the same room as sterile drug preparation
• Staff wearing non-sterile gloves during aseptic operations with exposed hair and skin
• A product labeled as 1.25 mg that actually contained 1.75 mg — a 40% dosing error
• A facility that approved drugs for distribution even after finding microbial contamination

One pharmacy voluntarily recalled all its sterile products. Another had to recall a lot due to lack of sterility assurance.

Hims Exits Compounded GLP-1 Market

In May 2026, Hims & Hers stopped selling its compounded GLP-1 pill after facing legal pressure from Eli Lilly. Hims was one of the highest-profile telehealth companies offering compounded GLP-1s. Their exit signals that the compounded-only telehealth model is contracting.

Eli Lilly vs. Empower Pharmacy

Eli Lilly's lawsuit against compounder Empower Pharmacy saw a partial dismissal in April 2026 — some claims were thrown out, but others are proceeding. The legal landscape remains uncertain and risky for compounding pharmacies.

New FDA-Approved Oral Option: Foundayo

On April 1, 2026, the FDA approved Foundayo (orforglipron) — a daily GLP-1 pill with no food restrictions. This is relevant because:

• Foundayo gives you an FDA-approved oral option that does not require compounding
• Eli Lilly's savings program offers it as low as $25/month for eligible patients
• CVS Caremark added Foundayo to its national formulary in May 2026, expanding insurance-covered access

If you've been using compounded semaglutide because you couldn't afford brand-name, Foundayo is worth checking.

State-Level Rules Are Growing

More states added their own compounding requirements in 2026:

• Texas and Florida — Additional inspections for compounding pharmacies
• California — Requires patient disclosure that compounded drugs are not FDA-approved
• New York — Proposed new compounding oversight legislation

FDA Warnings About Compounded GLP-1s

The FDA has issued multiple warnings about compounded GLP-1 products. Here's what they've flagged:

Quality and Purity Concerns

• No FDA pre-market review — Unlike brand-name drugs, compounded versions don't go through the FDA's rigorous approval process for safety, efficacy, and manufacturing quality
• Variable production standards — Quality depends entirely on the individual pharmacy. Some are excellent; others are not
• Impurities — Some compounded products have been found to contain contaminants or incorrect amounts of active ingredient

Salt Form Issues

This is one of the most important safety concerns:

• Brand-name semaglutide uses semaglutide base
• Some compounded versions use semaglutide sodium salt or semaglutide acetate salt
• The salt forms are different molecules from the FDA-approved base form
• The FDA has stated that salt forms have not been demonstrated to be safe or effective
• Some patients using salt-form compounded products have reported worse side effects or no therapeutic benefit

The FDA specifically warned that "the salt forms of semaglutide are different active ingredients than the active ingredient in FDA-approved Ozempic and Wegovy."

Adverse Event Reports

The FDA has received reports of adverse events from patients using compounded GLP-1 products, including:

• Severe nausea and vomiting
• Hospitalizations
• Ineffective treatment (no blood sugar control or weight loss)

The Risks, Explained

Quality and Safety

• Not FDA-approved — The specific compounded product you receive has not been evaluated by the FDA
• No FDA oversight of manufacturing — While compounding pharmacies are regulated, the level of oversight is different from FDA-approved manufacturers
• Production quality varies widely — A 503A traditional compounding pharmacy operates differently from a 503B outsourcing facility (which has stricter standards)
• May contain harmful impurities — Without standardized manufacturing, contamination risk is higher

Effectiveness

• Dosing may be inaccurate — FDA inspectors found a 40% dosing error in one product labeled as 1.25 mg that actually contained 1.75 mg
• May not work as well as brand-name versions — Especially if salt forms are used instead of the base molecule
• No bioequivalence guarantee — There's no requirement to prove the compounded version works the same way as the brand-name drug

Legal and Regulatory Risk

• Shortage exemption no longer applies to semaglutide — With semaglutide off the shortage list as of May 2026, compounding it is now legally riskier
• Regulatory landscape is shifting — The FDA has taken enforcement action. States are adding their own rules. Your source could be shut down
• No recourse if something goes wrong — If you have an adverse reaction, you don't have the same legal protections as with an FDA-approved product

FDA-Approved GLP-1 Medications

These are the safe, tested, FDA-approved options:

See our GLP-1 Pills: FDA-Approved Oral Options guide for more on oral alternatives.

How to Vet a Compounding Pharmacy (If You Choose to Go This Route)

If cost or availability drives you toward compounded GLP-1s, take these precautions:

1. Verify the Pharmacy's Credentials

• Check that the pharmacy is licensed in your state
• Look for 503B outsourcing facility status (higher standards than 503A)
• Verify they require a valid prescription from a licensed healthcare provider

2. Ask About the Active Ingredient

• Demand semaglutide base, not salt forms — Ask specifically: "Is this semaglutide base or semaglutide sodium/acetate salt?"
• If they can't or won't answer, walk away
• Request a certificate of analysis (CoA) from their API (active pharmaceutical ingredient) supplier

3. Check for Transparency

• Reputable compounders will provide lot numbers, expiration dates, and storage instructions
• They should be willing to answer questions about their sourcing and testing processes
• Be wary of prices that seem unrealistically low (under $200/month is a red flag for semaglutide base)

4. Look for Third-Party Testing

• The best compounding pharmacies have their products tested by independent labs
• Ask if they can provide potency and sterility test results

For the full four-question verification checklist, see Compounded Semaglutide in 2026: What Changed, What's Legal, What to Verify.

Safer Ways to Save on GLP-1 Medications

Before turning to compounding, explore these options:

Manufacturer Savings Programs

• Novo Nordisk (Wegovy/Ozempic): Savings cards can reduce cost to as low as $99/month for commercially insured patients
• Eli Lilly (Mounjaro/Zepbound): Zepbound savings programs available for eligible patients — as low as $25/month
• Both companies offer patient assistance programs for uninsured, low-income individuals

Foundayo: FDA-Approved Pill Option

Foundayo (orforglipron) is now available as an FDA-approved daily GLP-1 pill:

• As low as $25/month with Eli Lilly's savings program for eligible patients
• No needles, no food restrictions
• Expanding insurance coverage (added to CVS Caremark formulary in May 2026)
• No compounding risks

Insurance Coverage

• Check your formulary — coverage is expanding
• See our insurance coverage guide for step-by-step instructions
• Many denials are overturned on appeal

Retail Pharmacy Programs

• Some pharmacies offer discount programs or cash-pay pricing
• Compare prices across pharmacies (Costco, Mark Cuban Cost Plus Drugs, etc.)
• See our cost comparison guide for current pricing

Red Flags: When to Walk Away

Avoid any product or provider that:

• Claims to be "generic Wegovy" or "generic Ozempic" (there is no FDA-approved generic yet)
• Costs dramatically less than pharmacy prices (under $100/month is almost certainly suspicious)
• Is marketed as "compounded" without requiring a prescription
• Comes from unknown online sources or social media sellers
• Promises unrealistic results ("lose 30 lbs in a month!")
• Won't tell you whether they use base or salt forms
• Doesn't require a medical consultation

Supplies for GLP-1 Injections

Whether you use brand-name or compounded GLP-1s, you will need:

• Alcohol prep pads — for cleaning your skin before each injection
• A sharps container — for safe needle disposal
• Electrolyte powder — for managing nausea and dehydration
• Magnesium glycinate — helps with constipation from slowed digestion

GLPSpot may earn from qualifying purchases.

The Bottom Line

Compounded GLP-1 medications carry real and documented risks — and the legal landscape just shifted. With semaglutide off the FDA shortage list as of May 2026, compounding pharmacies are supposed to stop making compounded semaglutide. The FDA found real safety problems at real pharmacies: carpeted cleanrooms, 40% dosing errors, contaminated products. Hims stopped selling its compounded GLP-1 pill. New state rules are in effect. And Foundayo now gives you an FDA-approved pill option with expanding insurance coverage.

If cost is the driving factor, explore manufacturer savings programs, Foundayo, insurance coverage, and retail pharmacy discounts first. If you do choose to use a compounded product, vet the pharmacy thoroughly, confirm they use semaglutide base (not salt forms), and monitor your response carefully.

Check the FDA Drug Shortage Database for current status. Ask the four questions. Verify the answers. And always explore FDA-approved options before assuming compounded is your only choice.

Use FDA-approved GLP-1 medications from licensed pharmacies whenever possible. This article is for informational purposes only and is not medical advice. Always consult your healthcare provider before starting or changing any medication.

Related Reading

• Compounded Semaglutide in 2026: What Changed, What's Legal, What to Verify
• Foundayo (Orforglipron): GLP-1 Pill With No Food Rules
• GLP-1 Cost Comparison 2026: What You'll Actually Pay
• GLP-1 Insurance Coverage: How to Get Approved
• GLP-1 Shortages & Backorders
• GLP-1 Pills: FDA-Approved Oral Options